- Conditions
- Dry Eye Syndromes
- Interventions
- Euphrasia-based homeopathic therapy, Cyclosporin solution
- Drug
- Lead sponsor
- University of Missouri-Columbia
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 1
- States / cities
- Columbia, Missouri
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1921–1944
of 12,552
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Clear Cell Renal Cell Carcinoma
- Interventions
- Sitravatinib, Nivolumab
- Drug
- Lead sponsor
- Mirati Therapeutics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Cancer of Rectum
- Interventions
- combination of drugs (chemoradiation (capecitabine and radiation) + FOLFOXIRI (Oxaliplatin, leucovorin, irinotecan, and fluorouracil)
- Drug
- Lead sponsor
- Rutgers, The State University of New Jersey
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 5
- States / cities
- Lakewood, New Jersey • Livingston, New Jersey • New Brunswick, New Jersey + 2 more
- Conditions
- Ovarian Cancer, Hepatocellular Carcinoma, Non-small Cell Lung Cancer, Bladder Cancer, Microsatellite Instability-High
- Interventions
- DPX-Survivac, Cyclophosphamide, Pembrolizumab
- Other · Drug
- Lead sponsor
- ImmunoVaccine Technologies, Inc. (IMV Inc.)
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 184 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 15
- States / cities
- Tucson, Arizona • Los Angeles, California • Boca Raton, Florida + 12 more
- Conditions
- Covid19
- Interventions
- LY3819253, Placebo, Remdesivir, VIR-7831, BRII-196/BRII-198, AZD7442, MP0420, PF-07304814
- Biological · Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 2,753 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 98
- States / cities
- Tucson, Arizona • Chula Vista, California • Fresno, California + 64 more
- Conditions
- Hemophilia A
- Interventions
- NXT007, Human Coagulation Factor VIII
- Combination Product · Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 138 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 2
- States / cities
- Aurora, Colorado • Iowa City, Iowa
- Conditions
- Lung Cancer, Nonsmall Cell
- Interventions
- Blood and tissue samples
- Other
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2035
- U.S. locations
- 2
- States / cities
- Charlotte, North Carolina • Winston-Salem, North Carolina
- Conditions
- Untreated Metastatic Pancreatic Ductal Adenocarcinoma
- Interventions
- Nivolumab, Albumin-bound paclitaxel, Paricalcitol, Cisplatin, Gemcitabine
- Drug
- Lead sponsor
- HonorHealth Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2024
- U.S. locations
- 1
- States / cities
- Scottsdale, Arizona
- Conditions
- Exocrine Pancreatic Insufficiency
- Interventions
- Liprotamase
- Drug
- Lead sponsor
- Anthera Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 11
- States / cities
- Hamden, Connecticut • Jacksonville, Florida • Chicago, Illinois + 7 more
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Capmatinib, Amivantamab
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 5
- States / cities
- Birmingham, Alabama • Cerritos, California • Los Angeles, California + 2 more
- Conditions
- Stress Disorders, Post-Traumatic, Smoking
- Interventions
- Cognitive Processing Therapy (CPT), Bupropion, nicotine replacement therapy (NRT), Integrated Care for Smoking Cessation (ICSC), smokefreeVET
- Behavioral · Drug
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Solid Tumors
- Interventions
- Ramucirumab (IMC-1121B), Irinotecan, Folinic acid, 5-Fluorouracil
- Biological · Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 5
- States / cities
- Detroit, Michigan • Las Vegas, Nevada • Cleveland, Ohio + 2 more
- Conditions
- Acne Scars
- Interventions
- Fraxel Restore (Non-ablative Fractional Laser), Fraxel Restore (Non-ablative fractional laser) and SkinPen (Microneedling Device)
- Device
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Hepatitis C Infection, HIV Infection
- Interventions
- Glecaprevir/Pibrentasvir (G/P)
- Drug
- Lead sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 11
- States / cities
- San Diego, California • San Francisco, California • Aurora, Colorado + 6 more
- Conditions
- Metastatic Breast Cancer
- Interventions
- tivozanib (AV-951) + paclitaxel
- Drug
- Lead sponsor
- AVEO Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • New York, New York
- Conditions
- Postmenopausal
- Interventions
- Diet - higher protein, Physical activity and resistance training
- Other · Behavioral
- Lead sponsor
- University of Arkansas, Fayetteville
- Other
- Eligibility
- Female only
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 2
- States / cities
- Fayetteville, Arkansas
- Conditions
- Ovarian Cancer, Endometrial Cancer
- Interventions
- everolimus and letrozole
- Drug
- Lead sponsor
- Sinai Hospital of Baltimore
- Other
- Eligibility
- 18 Years to 80 Years · Female only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2014
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Painful Diabetic Neuropathy
- Interventions
- SCS in combination with CMM
- Combination Product
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 22 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Oshkosh, Wisconsin
- Conditions
- Locally Advanced or Metastatic Solid Tumors
- Interventions
- LUNA18, Cetuximab
- Drug
- Lead sponsor
- Chugai Pharmaceutical
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 128 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 13
- States / cities
- Davis, California • Boston, Massachusetts • Detroit, Michigan + 9 more
- Conditions
- HIV-1 Infection
- Interventions
- Pravastatin sodium, Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate
- Drug
- Lead sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
- Network
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 9
- States / cities
- Los Angeles, California • Torrance, California • St Louis, Missouri + 6 more
- Conditions
- Oral Mucositis
- Interventions
- Photobiomodulation - INTRAORAL, Photobiomodulation - EXTRAORAL, Photobiomodulation - INTRAORAL and EXTRAORAL
- Device
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 4 Years and older
- Enrollment
- 78 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung
- Interventions
- PF-07985045, Gemcitabine, Nab-paclitaxel, Cetuximab, Fluorouracil, Oxaliplatin, Leucovorin, Bevacizumab, Pembrolizumab, Sasanlimab, pemetrexed, Cisplatin, Paclitaxel, Carboplatin, PF-07284892
- Drug · Combination Product
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 12
- States / cities
- Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 6 more
- Conditions
- Non-small Cell Lung Cancer, Histiocytic Neoplasm, Histiocytosis, BRAF Gene Mutation, BRAF V600E, BRAF V600 Mutation, BRAF Mutation-Related Tumors, BRAF, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Lung Cancer, Recurrent Lung Cancer, Recurrent Lung Non-Small Cell Carcinoma, NSCLC, Solid Tumor, Solid Carcinoma, KRAS G12D, KRAS G12V, KRAS Mutation-Related Tumors, NRAS Gene Mutation, Thyroid Cancer, Thyroid Carcinoma, Colorectal Cancer, Colorectal Carcinoma, Recurrent Histiocytic and Dendritic Cell Neoplasm, Brain Metastases, Recurrent NSCLC, KRAS G13C, Acquired Resistance to KRAS G12C Inhibitor, KRAS G12A, KRAS G12F, KRAS G12R, KRAS G13D
- Interventions
- S241656, FOLFOX6/FOLFOX7, FOLFIRI, Cetuximab, Panitumumab, Gemcitabine, Nab-paclitaxel
- Drug
- Lead sponsor
- Institut de Recherches Internationales Servier
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 554 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 21
- States / cities
- Gilbert, Arizona • Los Angeles, California • San Francisco, California + 15 more
- Conditions
- Multiple Myeloma
- Interventions
- Group A: Carfilzomib & Non-IMiD Regimen, Group B: Carfilzomib & IMiD containing regimen.
- Drug
- Lead sponsor
- Oncotherapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 9
- States / cities
- Encinitas, California • Salinas, California • Santa Maria, California + 6 more